The involvement of TRPV1 and TRPA1 in mediating craniofacial muscle nociception and mechanical hyperalgesia was investigated in male Sprague-Dawley rats. First, we confirmed the expression of TRPV1 in masseter afferents in rat trigeminal ganglia (TG), and provided new data that TRPA1 is also expressed in primary afferents innervating masticatory muscles in double-labeling immunohistochemistry experiments. We then examined whether the activation of each TRP channel in the masseter muscle evokes acute nocifensive responses and leads to the development of masseter hypersensitivity to mechanical stimulation using the behavioral models that have been specifically designed and validated for the craniofacial system. Intramuscular injections with specific agonists for TRPV1 and TRPA1, capsaicin and mustard oil (MO), respectively, produced immediate nocifensive hindpaw responses followed by prolonged mechanical hyperalgesia in a concentration-dependent manner. Pretreatment of the muscle with a TRPV1 antagonist, capsazepine, effectively attenuated the capsaicin-induced muscle nociception and mechanical hyperalgesia. Similarly, pretreatment of the muscle with a selective TRPA1 antagonist, AP18, significantly blocked the MO-induced muscle nociception and mechanical hyperalgesia. We confirmed these data with another set of selective antagonist for TRPV1 and TRPA1, AMG9810 and HC030031, respectively. Collectively, these results provide compelling evidence that TRPV1 and TRPA1 can functionally contribute to muscle nociception and hyperalgesia, and suggest that TRP channels expressed in muscle afferents can engage in the development of pathologic muscle pain conditions. Ó
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Introduction
Chronic muscle pain conditions, such as temporomandibular disorders (TMD), are characterized by localized myalgia and tenderness of the muscle upon manual palpation [23] . These conditions are also associated with a reduced maximum force output and a limited range of movements [36, 41] , which could result from sensitization of muscle nociceptors [39] . Thus, prominent features associated with muscle pain condition are changes in mechanical sensitivity of muscle tissue. However, the pathophysiological mechanisms leading to the development of mechanical hyperalgesia are still poorly understood.
Recent studies indicate that several members of the transient receptor potential (TRP) family, namely TRPV1 and TRPA1 function as either sensory transducers for noxious mechanical stimuli or play an essential role in the development of mechanical hypersensitivity under various pain conditions [35] . Both TRP channels are expressed in distinct subgroups of primary afferent neurons: TRPV1 is predominantly expressed in small diameter dorsal root ganglia (DRG) and TG neurons [12, 27] and TRPA1 in a subset of TRPV1 containing neurons [9, 29, 51] . While data on cellular and molecular mechanisms of each of these channels have been accumulating [16,17,37,46,57] our knowledge of the functional contributions of these channels in muscle pain conditions is limited. Given the clinical relevance of the mechanical nature of muscular hyperalgesia it becomes pertinent to evaluate specific contributions of these TRP channels and the cellular mechanisms underlying the development and maintenance of such conditions. TRPV1 is expressed in a small subpopulation of muscle afferents in DRG, and direct injection with a TRPV1 agonist, capsaicin, activates muscle nociceptors while pharmacological blockade of TRPV1 reduces exercise-induced muscle hyperalgesia in the rat [19, 24] . Intramuscular capsaicin in human subjects activates muscle nociceptors and evokes an intense deep pain sensation as well as mechanical hyperalgesia [5, 6, 38] . Capsaicin injection into the masseter muscle evokes mechanical hypersensitivity in rats [50] suggesting functional TRPV1 channels are expressed in masseteric afferents. Similarly, masseteric injections with a potent TRPA1 agonist, mustard oil (MO), evokes concentration-dependent nocifensive responses and inflammation in rats [33, 49] , also implicating TRPA1 in pain arising from craniofacial deep tissue. While TRPV1 is shown to be expressed in a subpopulation of masseteric
